Table 1.
Plasma concentrations of individual cis- and trans-EETs in WKY and SHR treated with vehicle or AUCB for 1 wk
| WKY |
SHR |
|||
|---|---|---|---|---|
| Vehicle | AUCB | Vehicle | AUCB | |
| 14,15- | ||||
| cis-EET | 5.8 ± 0.6 | 5.2 ± 0.7 | 4.5 ± 0.6 | 4.4 ± 0.7 |
| trans-EET | 1.6 ± 0.2 | 3.4 ± 0.6* | 1.1 ± 0.1 | 2.3 ± 0.7* |
| 11,12- | ||||
| cis-EET | 2.1 ± 0.3 | 2.7 ± 0.3 | 1.4 ± 0.3 | 1.6 ± 0.2 |
| trans-EET | 2.0 ± 0.2 | 3.6 ± 0.8* | 0.9 ± 0.1 | 2.0 ± 0.5* |
| 8,9- | ||||
| cis-EET | 4.9 ± 0.4 | 3.3 ± 0.4 | 3.2 ± 0.4 | 3.0 ± 0.3 |
| trans-EET | 1.8 ± 0.3 | 2.7 ± 0.7* | 0.9 ± 0.1 | 1.9 ± 0.3* |
| 5,6- | ||||
| cis-EET | 5.5 ± 0.4 | 4.8 ± 0.3 | 3.2 ± 0.4 | 3.1 ± 0.2 |
| trans-EET | 2.4 ± 0.1 | 2.8 ± 0.5 | 1.2 ± 0.1 | 1.7 ± 0.3 |
| Total | ||||
| cis-EET | 18.3 ± 1.4 | 16.0 ± 1.5 | 12.3 ± 1.6 | 12.1 ± 1.3 |
| trans-EET | 7.8 ± 0.5 | 12.5 ± 1.9* | 4.1 ± 0.2 | 7.9 ± 1.5* |
| Overall | ||||
| EETs | 26.1 ± 1.8 | 28.5 ± 3.2 | 16.4 ± 1.6 | 20.0 ± 2.4* |
Values were determined by LC/MS/MS and expressed as means ± SE (ng/ml); n = 6–8 rats in each group. EET, epoxyeicosatrienoic acid; AUCB, cis-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid. Eleven-week-old Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats were treated with vehicle or AUCB (2 mg · kg−1 · day−1 in the drinking water) for 7 days.
*
P < 0.05 compared with plasma concentrations of vehicle rats of the same strain.